Main content

    Epilepsy Clinical Trials

    California Pacific Epilepsy Program Opens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Active Trials

    Title: A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)
    Description: This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity
    Investigator: David King-Stephens, MD
    Eligibility: Subjects with a clinical diagnosis of partial or generalized epilepsy who have been admitted to the institution's EMU for seizure characterization or pre-surgical evaluation
    Status: Open to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study EMU

    Title: A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
    Description: A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
    Investigator: Kenneth Laxer, MD
    Eligibility: Subjects with refractory complex partial seizures who are beginning treatment with Vigabatrin (Sabril®)
    Status: Closed to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study Lundbeck Vision

    Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
    Description: A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
    Investigator: David King-Stephens, MD
    Eligibility: Subjects with a clinical diagnosis of primary generalized tonic-clonic seizures
    Status: Closed to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study Eisai 332

    Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures
    Description: Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
    Investigator: David King-Stephens, MD
    Eligibility: Subjects with partial onset seizures
    Status: Closed to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study UCB N01358

    • updated October 2014